Genentech's divarasib cuts death risk 44% in Phase III KRAS G12C NSCLC trial

Genentech reported Sunday that divarasib lowered death risk by 44% in the Phase III Krascendo 1 trial in previously treated KRAS G12C NSCLC, with fewer TRAE discontinuations (4.8% versus 11.7%) than sotorasib or adagrasib.

Detected & updated continuously · Source: Nebula